Recurrent Atrial Fibrillation Market to Set Phenomenal Growth Rate and Forecast Analysis 2020 – 2027 | Emergen Research

 

Market Size – USD 9.51 billion in 2019, Market Growth - CAGR of 13.2%, Market Trends – Advancements in device technology.

The global Recurrent Atrial Fibrillation Market is expected to reach USD 25.93 Billion by 2027, according to a new report by Emergen Research. The increasing incidence of recurrent atrial fibrillation is majorly associated with recurrent paroxysmal atrial fibrillation patients, with the occurrence of a family history of AFib, high blood pressure, sleep apnea, overuse of stimulants, alcohol consumption, obesity, thyroid disorders, diabetes, lung disease, severe infections, and stress.

Factors driving this market include augmenting incidence rate of recurrent atrial fibrillation, new product launches for effective treatment of recurrent events, and improved reimbursement scenarios for recurrent AFib treatment drugs along with technological advancements are expected to become the most common growth factors globally in the coming years. Moreover, healthcare experts from the University of Pennsylvania have estimated that patients admitted to intensive care units for COVID-19 treatment are more likely to suffer from arrhythmia and atrial fibrillation. This would be alarming for cardiac patients and would lead to increased sales of atrial fibrillation associated drugs.

To get holistic FREE SAMPLE of the report, please click: https://www.emergenresearch.com/request-sample-form/71

North America is dominating the revenue share of the industry owing to availability of technologically advanced products, efficient treatments, favourable reimbursement scenarios, increase in purchasing power of the people and high occurrence rate of Recurrent Atrial Fibrillation among elderly population. However, high cost linked with the treatment, unawareness among people and strict government policies among other shortcomings are likely to restrain the industry growth.

The leading manufactures in the market include Novartis International AG, Johnson & Johnson Services, AbbVie, AstraZeneca, Amgen, Celgene Corporation, Bristol-Myers Squibb Company, Bausch Health Companies, Eli Lilly and Company and Pfizer among other companies

Browse complete report description and visit our website @ https://www.emergenresearch.com/industry-report/recurrent-atrial-fibrillation-market

Regional Scope: North America; Europe; Asia Pacific; Central & South America; MEA

Product Outlook (Revenue, USD Billion; 2017-2027)

1. Device
2. Surgical Devices
3. Maze Surgery
4. Catheter Ablation
5. Radiofrequency Catheter Ablation
6. Conventional RF Ablation Catheters
7. Irrigated-tip RF Ablation Catheters
8. Cryoablation
9. Microwave Based Catheter Ablation
10. Laser Based Catheter Ablation
11. Navigational Advanced Mapping Accessories

Application Outlook (Revenue, USD Billion; 2017-2027)

1. EP Ablation
2. Diagnostic
3. Surgical Cardiac

End Users Outlook (Revenue, USD Billion; 2017-2027)

1. Hospitals
2. Cardiac Centers
3. Ambulatory Care Centers

North America accounted for the largest market share of approximately, 37.2% in the global Recurrent Atrial Fibrillation market in 2019 primarily due to growing incidences of chronic asthma and rhinosinusitis symptoms along with competent infrastructure and favorable reimbursement scenarios. Owing to such promising market drivers, the North American market is anticipated to grow significantly through the forecast period.

Interested in this report? Get your FREE sample now! https://www.emergenresearch.com/request-sample-form/71

Table of Content

Chapter 1. Methodology & Sources

    1.1. Market Definition

    1.2. Research Scope

    1.3. Methodology

    1.4. Research Sources

          1.4.1. Primary

          1.4.2. Secondary

          1.4.3. Paid Sources

    1.5. Market Estimation Technique

Chapter 2. Executive Summary

    2.1. Summary Snapshot, 2019-2027

Chapter 3. Key Insights

Chapter 4. Recurrent Atrial Fibrillation Market Segmentation & Impact Analysis

    4.1. Recurrent Atrial Fibrillation Market Material Segmentation Analysis

    4.2. Industrial Outlook

          4.2.1. Market indicators analysis

          4.2.2. Market drivers analysis

                    4.2.2.1. Rising incidence of heart diseases

                    4.2.2.2. Growing demand of the minimally invasive procedures

                    4.2.2.3. Technological advancement

    4.3. Market restraints analysis

                    4.3.1.1. High Cost of devices

    4.4. Technological Insights

    4.5. Regulatory Framework

    4.6. Porter’s Five Forces Analysis

    4.7. Competitive Metric Space Analysis

    4.8. Price trend Analysis

    4.9. Covid-19 Impact Analysis

Chapter 5. Recurrent Atrial Fibrillation Market By Product Insights & Trends, Revenue (USD Million)

    5.1. Product Dynamics & Market Share, 2019 & 2027

          5.1.1. Device

                    5.1.1.1. Surgical Devices

                                 5.1.1.1.1. Maze Surgery

                                 5.1.1.1.2. Catheter Ablation

                                 5.1.1.1.3. Radiofrequency Catheter Ablation

                                                5.1.1.1.3.1. Conventional RF Ablation Catheters

                                                5.1.1.1.3.2. Irrigated-tip RF Ablation Catheters

                                 5.1.1.1.4. Cryoablation

                                 5.1.1.1.5. Microwave Based Catheter Ablation

                                 5.1.1.1.6. Laser Based Catheter Ablation

                                 5.1.1.1.7. Navigational Advanced Mapping Accessories

                    5.1.1.2. Non-Surgical Devices

                                 5.1.1.2.1. Electric Cardioversion

                                 5.1.1.2.2. EP Ablation Catheters

                                 5.1.1.2.3. EP Diagnostic Catheter

                                 5.1.1.2.4. Conventional Diagnostic Catheters

                                                5.1.1.2.4.1. Fixed Diagnostic Catheters

                                                5.1.1.2.4.2. Steerable Diagnostic Catheters

                                 5.1.1.2.5. Advanced Diagnostic Catheters

                                 5.1.1.2.6. Mapping and Recording Systems

                                 5.1.1.2.7. Cardiac Monitors or Loop Recorders

                                 5.1.1.2.8. Access Devices

                                 5.1.1.2.9. Left Atrial Appendage and Closure Devices

                                 5.1.1.2.10. Intracardiac Echocardiography (ICE) Systems

          5.1.2. Drugs

                    5.1.2.1. Dabigatran (Pradaxa)

                    5.1.2.2. Rivaroxaban (Xarelto)

                    5.1.2.3. Apixaban (Eliquis)

                    5.1.2.4. Edoxaban (Savaysa)

                    5.1.2.5. Warfarin (Coumadin)

                    5.1.2.6. Others

Chapter 6. Recurrent Atrial Fibrillation Market By Application Insights & Trends Revenue (USD Million)

    6.1. Application Dynamics & Market Share, 2019 & 2027

          6.1.1. EP Ablation

          6.1.2. Diagnostic

          6.1.3. Surgical Cardiac

Continue…

Thank you for reading our report. For further information or queries about the report or customization options, please get in touch with us. We will ensure your report is tailored according to your requirements.